Invenra
Madison, US · Founded 2011 · Delaware corporation · 2 known investors
Invenra develops proprietary platform technologies to discover and develop novel bi- and multi-specific antibody therapies, with an initial focus on oncology. The company is advancing pipelines of antibody candidates with partners and intends to expand into additional disease categories.
Founders & leadership
Invenra was founded in 2011 by Roland Green.
RG
Roland GreeninFounder · CEO
Board
EN
Emile NuwaysirBoard director
SR
Stan RoseBoard director
RL
Richard LesniewskiBoard director
DS
David SnyderBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$18.3M disclosed across 6 rounds · 2012–2018
▶$7.1MraisedOct 2018 · 23 investors · PharmaceuticalsRule 506(b)
▶$7.1MraisedOct 2018 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roland GreenExecutive Officer, Director
- Paul WeissDirector
- Emile NuwaysirDirector
- Richard LesniewskiDirector
- Stan RoseDirector
- David SnyderDirector
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedOct 2017 · 25 investors · PharmaceuticalsRule 506(b)
▶$2.9MraisedOct 2017 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David SnyderDirector
- Richard LesniewskiDirector
- Emile NuwaysirDirector
- Roland GreenExecutive Officer, Director
- Stan RoseDirector
- Offering amount
- $6M
- Amount sold
- $2.9M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJul 2016 · 27 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJul 2016 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stan RoseDirector
- Richard LesniewskiDirector
- David SnyderDirector
- Emile NuwaysirDirector
- Roland GreenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$2MraisedAug 2015 · 28 investors · PharmaceuticalsRule 506(b)
▶$2MraisedAug 2015 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Emile NuwaysirDirector
- Stan RoseDirector
- Roland GreenExecutive Officer, Director
- David SnyderDirector
- Richard LesniewskiDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$2MraisedJan 2015 · 25 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJan 2015 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Emile NuwaysirDirector
- Stan RoseDirector
- Richard LesniewskiDirector
- David SnyderDirector
- Roland GreenExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1.2MraisedJan 2012 · 18 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedJan 2012 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roland GreenExecutive Officer, Director
- Emile NuwaysirDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06, 46
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA29 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
VISTERRA, INC.20 shared keywordsA biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
Companies competing with Invenra for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Invenra do?
- Invenra develops proprietary platform technologies to discover and develop novel bi- and multi-specific antibody therapies, with an initial focus on oncology. The company is advancing pipelines of antibody candidates with partners and intends to expand into additional disease categories.
- Who founded Invenra?
- Invenra was founded by Roland Green in 2011.
- Who are Invenra's investors?
- Invenra's investors include Venture Management, Wisconsin Investment Partners.
- How much funding has Invenra raised?
- Invenra has disclosed $18.3M raised across 6 rounds.
- Where is Invenra headquartered?
- Invenra is headquartered in Madison, US.